SCH 546738CXCR antagonist CAS# 906805-42-3 |
2D Structure
- SCH 563705
Catalog No.:BCC1933
CAS No.:473728-58-4
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 906805-42-3 | SDF | Download SDF |
PubChem ID | 11995774 | Appearance | Powder |
Formula | C23H31Cl2N7O | M.Wt | 492.44 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : 4.5 mg/mL (9.14 mM; Need ultrasonic) H2O : < 0.1 mg/mL (insoluble) | ||
Chemical Name | 3-amino-6-chloro-5-[(3S)-4-[1-[(4-chlorophenyl)methyl]piperidin-4-yl]-3-ethylpiperazin-1-yl]pyrazine-2-carboxamide | ||
SMILES | CCC1CN(CCN1C2CCN(CC2)CC3=CC=C(C=C3)Cl)C4=NC(=C(N=C4Cl)C(=O)N)N | ||
Standard InChIKey | UYDYJFWSPRQEAX-KRWDZBQOSA-N | ||
Standard InChI | InChI=1S/C23H31Cl2N7O/c1-2-17-14-31(23-20(25)28-19(22(27)33)21(26)29-23)11-12-32(17)18-7-9-30(10-8-18)13-15-3-5-16(24)6-4-15/h3-6,17-18H,2,7-14H2,1H3,(H2,26,29)(H2,27,33)/t17-/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | SCH 546738 is a novel, potent and non-competitive CXCR3 antagonist, the affinity constant (Ki) of SCH 546738 binding to human CXCR3 receptor is determined to be 0.4 nM in multiple experiments.In Vitro:The affinity of SCH 546738 binding to human CXCR3 receptor is determined by competition binding analysis using 35S radiolabeled SCH 535390 (a sulfonamide analog of the CXCR3 compound series with a Kd of 0.6 nM) as a competitive tracer. In addition, SCH 546738 displaces radiolabeled CXCL10 and CXCL11 from human CXCR3 with IC50 ranging from 0.8 to 2.2 nM in a non-competitive manner. SCH 546738 potently and specifically inhibits CXCR3-mediated chemotaxis in human activated T cells with IC90 about 10 nM. Competition of human CXCL10 and CXCL11 binding to human CXCR3 by SCH 546738 is determined at various concentrations of [125I]hCXCL10 and [125I]hCXCL11 around the Kd (50-100 pM) for the receptor. The IC50 of SCH 546738 is constant (~1 or 2 nM) and independent of the input concentrations of either [125I]hCXCL10 (25-500 pM) or [125I]hCXCL11 (12.5-250 pM), respectively[1].In Vivo:SCH 546738 has strong cross-species activities with IC50 of 1.3 nM, 6.4 nM, 5.9 nM and 4.2 nM in inhibiting the binding of [125I]hCXCL10 to CXCR3 of monkey, dog, mouse and rat origin, respectively. SCH 546738 is a selective and potent CXCR3 antagonist with a good PK for in vivo studies. In addition, SCH 546738 has a favourable pharmacokinetic profile in rodents, the plasma concentrations of SCH 546738 in Lewis rat and C57BL/6 mouse over 24 hr post-dose. The AUC (0-24 hr) is 7.7 μM.hr in Lewis rat 10 mg/kg (mpk) and is 12.6 μM.hr in C57BL/6 mouse 30 mpk[1]. References: |
SCH 546738 Dilution Calculator
SCH 546738 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.0307 mL | 10.1535 mL | 20.307 mL | 40.6141 mL | 50.7676 mL |
5 mM | 0.4061 mL | 2.0307 mL | 4.0614 mL | 8.1228 mL | 10.1535 mL |
10 mM | 0.2031 mL | 1.0154 mL | 2.0307 mL | 4.0614 mL | 5.0768 mL |
50 mM | 0.0406 mL | 0.2031 mL | 0.4061 mL | 0.8123 mL | 1.0154 mL |
100 mM | 0.0203 mL | 0.1015 mL | 0.2031 mL | 0.4061 mL | 0.5077 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
SCH 546738is a novel,selective,non-competitive and potent antagonist of CXCR with Ki value of 0.4nM for human CXCR3 receptor in multiple experiments [1].
The affinity of SCH 546738 (Kd) binding to human CXCR3 receptor was determined to be 0.6nM. Competition of human CXCL10 and CXCL11 binding to human CXCR3 bySCH 546738 was determined with the Kd values ranging from 50 to 100pM. These results have indicated that SCH546738 is a non-competitive antagonist of both CXCL10and CXCL11 binding to CXCR3.
Apart from these, SCH 546738 has strong cross-species activities with IC50 values of 1.3nM, 6.4nM, 5.9nM and 4.2nM in inhibiting the binding of hCXCL10 to CXCR3 of monkey, dog, mouse and rat, respectively [1].
References:
[1] Jenh CH, Cox MA, Cui L, Reich EP, Sullivan L, Chen SC, Kinsley D, Qian S, Kim SH, Rosenblum S, Kozlowski J, Fine JS, Zavodny PJ, Lundell D. A selective and potent CXCR3 antagonist SCH 546738 attenuates the development of autoimmune diseases and delays graft rejection.BMC Immunol. 2012 Jan 10;13(1):2. [Epub ahead of print]
- Parvifolixanthone B
Catalog No.:BCN7421
CAS No.:906794-57-8
- Parvifolixanthone A
Catalog No.:BCN7354
CAS No.:906794-56-7
- AN-2728
Catalog No.:BCC1361
CAS No.:906673-24-3
- Teneligliptin hydrobromide
Catalog No.:BCC1992
CAS No.:906093-29-6
- Neochlorogenic acid
Catalog No.:BCN4450
CAS No.:906-33-2
- CGK733
Catalog No.:BCC3911
CAS No.:905973-89-9
- Isopsoralenoside
Catalog No.:BCN3197
CAS No.:905954-18-9
- Psoralenoside
Catalog No.:BCN3196
CAS No.:905954-17-8
- Scutebarbatine B
Catalog No.:BCN4449
CAS No.:905929-95-5
- Tivantinib (ARQ 197)
Catalog No.:BCC3688
CAS No.:905854-02-6
- Sorghumol acetate
Catalog No.:BCN4448
CAS No.:90582-47-1
- Sorghumol
Catalog No.:BCN4447
CAS No.:90582-44-8
- Methyl 1,4-bisglucosyloxy-3-prenyl-2-naphthoate
Catalog No.:BCN7597
CAS No.:90685-26-0
- 5-Hydroxysophoranone
Catalog No.:BCN6842
CAS No.:90686-12-7
- Ethyl beta-carboline-1-propionate
Catalog No.:BCN1311
CAS No.:90686-24-1
- (S)-4-Benzyl-2-oxazolidinone
Catalog No.:BCC8401
CAS No.:90719-32-7
- Musellactone
Catalog No.:BCN7183
CAS No.:907583-51-1
- Atosiban
Catalog No.:BCC5314
CAS No.:90779-69-4
- 6,8-Di-O-methylcitreoisocoumarin
Catalog No.:BCN7380
CAS No.:908098-80-6
- SNX-2112
Catalog No.:BCC2132
CAS No.:908112-43-6
- PF-04929113 (SNX-5422)
Catalog No.:BCC2130
CAS No.:908115-27-5
- Cyclo(Ile-Ala)
Catalog No.:BCN2429
CAS No.:90821-99-1
- Goshonoside F1
Catalog No.:BCN6444
CAS No.:90851-24-4
- Goshonoside F5
Catalog No.:BCN6442
CAS No.:90851-28-8
A selective and potent CXCR3 antagonist SCH 546738 attenuates the development of autoimmune diseases and delays graft rejection.[Pubmed:22233170]
BMC Immunol. 2012 Jan 10;13:2.
BACKGROUND: The CXCR3 receptor and its three interferon-inducible ligands (CXCL9, CXCL10 and CXCL11) have been implicated as playing a central role in directing a Th1 inflammatory response. Recent studies strongly support that the CXCR3 receptor is a very attractive therapeutic target for treating autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis and psoriasis, and to prevent transplant rejection. We describe here the in vitro and in vivo pharmacological characterizations of a novel and potent small molecule CXCR3 antagonist, SCH 546738. RESULTS: In this study, we evaluated in vitro pharmacological properties of SCH 546738 by radioligand receptor binding and human activated T cell chemotaxis assays. In vivo efficacy of SCH 546738 was determined by mouse collagen-induced arthritis, rat and mouse experimental autoimmune encephalomyelitis, and rat cardiac transplantation models. We show that SCH 546738 binds to human CXCR3 with a high affinity of 0.4 nM. In addition, SCH 546738 displaces radiolabeled CXCL10 and CXCL11 from human CXCR3 with IC50 ranging from 0.8 to 2.2 nM in a non-competitive manner. SCH 546738 potently and specifically inhibits CXCR3-mediated chemotaxis in human activated T cells with IC90 about 10 nM. SCH 546738 attenuates the disease development in mouse collagen-induced arthritis model. SCH 546738 also significantly reduces disease severity in rat and mouse experimental autoimmune encephalomyelitis models. Furthermore, SCH 546738 alone achieves dose-dependent prolongation of rat cardiac allograft survival. Most significantly, SCH 546738 in combination with CsA supports permanent engraftment. CONCLUSIONS: SCH 546738 is a novel, potent and non-competitive small molecule CXCR3 antagonist. It is efficacious in multiple preclinical disease models. These results demonstrate that therapy with CXCR3 antagonists may serve as a new strategy for treatment of autoimmune diseases, including rheumatoid arthritis and multiple sclerosis, and to prevent transplant rejection.